These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38513335)

  • 1. Comparative effectiveness and mortality of colistin monotherapy versus colistin-fosfomycin combination therapy for the treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections: A propensity score analysis.
    Katip W; Rayanakorn A; Oberdorfer P; Taruangsri P; Nampuan T; Okonogi S
    J Infect Public Health; 2024 May; 17(5):727-734. PubMed ID: 38513335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
    van Duin D; Lok JJ; Earley M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Doi Y; Kaye KS; Fowler VG; Paterson DL; Bonomo RA; Evans S;
    Clin Infect Dis; 2018 Jan; 66(2):163-171. PubMed ID: 29020404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility profile, resistance mechanisms & efficacy ratios of fosfomycin, nitrofurantoin & colistin for carbapenem-resistant
    Amladi AU; Abirami B; Devi SM; Sudarsanam TD; Kandasamy S; Kekre N; Veeraraghavan B; Sahni RD
    Indian J Med Res; 2019 Feb; 149(2):185-191. PubMed ID: 31219082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of colistin-based regimens on mortality compared to other antimicrobials in patients with carbapenem-resistant Enterobacterales bacteremia in South African hospitals: a cross-sectional study.
    Ngoma N; Perovic O; de Voux A; Musekiwa A; Shuping L;
    BMC Infect Dis; 2024 Jun; 24(1):561. PubMed ID: 38840122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
    Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin- and carbapenem-resistant Enterobacteriaceae.
    Freire MP; de Oliveira Garcia D; Cury AP; Francisco GR; Dos Santos NF; Spadão F; Bueno MFC; Camargo CH; de Paula FJ; Rossi F; Nahas WC; David-Neto E; Pierrotti LC
    Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):755-765. PubMed ID: 30680569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High rate of colistin and fosfomycin resistance among carbapenemase-producing Enterobacteriaceae in Turkey.
    Süzük Yıldız S; Kaşkatepe B; Şimşek H; Sarıgüzel FM
    Acta Microbiol Immunol Hung; 2019 Mar; 66(1):103-112. PubMed ID: 30403361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbapenem and colistin resistance in children with Enterobacteriaceae infections.
    Haytoğlu Z; Gündeşlioğlu ÖÖ; Yıldızdaş D; Kocabaş E; Alabaz D; Horoz ÖÖ
    Turk J Pediatr; 2020; 62(5):778-786. PubMed ID: 33108080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short versus long course of colistin treatment for carbapenem-resistant A. baumannii in critically ill patients: A propensity score matching study.
    Katip W; Rayanakorn A; Oberdorfer P; Taruangsri P; Nampuan T
    J Infect Public Health; 2023 Aug; 16(8):1249-1255. PubMed ID: 37295057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia.
    Hakeam HA; Alsahli H; Albabtain L; Alassaf S; Al Duhailib Z; Althawadi S
    Int J Infect Dis; 2021 Aug; 109():1-7. PubMed ID: 34091006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of carbapenem-resistant Enterobacteriaceae infections.
    Durante-Mangoni E; Andini R; Zampino R
    Clin Microbiol Infect; 2019 Aug; 25(8):943-950. PubMed ID: 31004767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections.
    Trecarichi EM; Tumbarello M
    Virulence; 2017 May; 8(4):470-484. PubMed ID: 28276996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections.
    Ku K; Pogue JM; Moshos J; Bheemreddy S; Wang Y; Bhargava A; Campbell M; Khandker N; Lephart PR; Chopra T; Hayakawa K; Martin ET; Abreu-Lanfranco O; Dhar S; Kaye KS; Marchaim D
    Am J Infect Control; 2012 Dec; 40(10):983-7. PubMed ID: 22440526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Options for treating carbapenem-resistant Enterobacteriaceae.
    Rafailidis PI; Falagas ME
    Curr Opin Infect Dis; 2014 Dec; 27(6):479-83. PubMed ID: 25259809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant
    Wang X; Wang Q; Cao B; Sun S; Zhang Y; Gu B; Li B; Liao K; Zhao F; Jin L; Jin C; Yang C; Pei F; Zhang Z; Wang H
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
    Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting.
    Aslan AT; Kırbaş E; Sancak B; Tanrıverdi ES; Otlu B; Gürsoy NC; Yılmaz YA; Tozluyurt A; Liste Ü; Bıçakcıgil A; Hazırolan G; Dağ O; Güven GS; Akova M;
    Int J Antimicrob Agents; 2022 Apr; 59(4):106554. PubMed ID: 35176476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Matched Case-Case-Control Study of the Impact of Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant
    Saito S; Hayakawa K; Tsuzuki S; Ishikane M; Nagashima M; Mezaki K; Sugiki Y; Tajima T; Matsunaga N; Ide S; Kinoshita N; Kusama Y; Fujitomo Y; Nakamoto T; Toda Y; Kaku M; Kodama EN; Ohmagari N
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33257451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case-control study.
    Teo JQ; Chang CW; Leck H; Tang CY; Lee SJ; Cai Y; Ong RT; Koh TH; Tan TT; Kwa AL
    Int J Antimicrob Agents; 2019 May; 53(5):657-662. PubMed ID: 30880229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenem-Containing Combination Antibiotic Therapy against Carbapenem-Resistant Uropathogenic
    Loose M; Link I; Naber KG; Wagenlehner FME
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.